Relapsed/refractory CLL to prior cBTKi, baseline BTK mutations, unmutated IGHV, bulky lymph nodes, XPO1 mutation and complex karyotype were more prevalent attributes in the pirtobrutinib progressive-disease subgroup. Here, XPO1 is linked to B-cell chronic lymphocytic leukemia.